Menu Search
Equities

HitGen Inc

688222:SHH

HitGen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.50
  • Today's Change-0.150 / -1.73%
  • Shares traded2.86m
  • 1 Year change-42.61%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year HitGen Inc grew revenues 12.64% from 329.65m to 371.32m while net income improved 61.16% from 25.27m to 40.72m.
Gross margin49.20%
Net profit margin10.77%
Operating margin11.31%
Return on assets2.60%
Return on equity3.36%
Return on investment2.76%
More ▼

Cash flow in CNYView more

In 2023, HitGen Inc did not generate a significant amount of cash. However, the company earned 125.21m from its operations for a Cash Flow Margin of 33.72%. In addition the company used 84.14m on investing activities and also paid 25.04m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share3.38
Tangible book value per share3.07
More ▼

Balance sheet in CNYView more

HitGen Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio16.96
Quick ratio16.53
Total debt/total equity0.17
Total debt/total capital0.1431
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 69.90%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
Div yield(5 year avg)0.14%
Div growth rate (5 year)--
Payout ratio (TTM)44.29%
EPS growth(5 years)-20.39
EPS (TTM) vs
TTM 1 year ago		27.26
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.